carmofur has been researched along with tamoxifen in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Easwaran, M; Manickam, M; Pillaiyar, T; Wendt, LL | 1 |
| Hoshino, S; Katsumata, K; Kimura, K; Tani, C; Yamamoto, K; Yamashita, S | 1 |
| Tominaga, T | 1 |
| Fukushima, H; Goya, T; Hanaoka, T; Matsuda, M; Sato, K; Tanaka, R | 1 |
| Asano, T; Danno, M; Fujiwara, J; Kimura, M; Nishi, T; Sano, M; Sasaki, M; Takashima, S; Tominaga, T; Yoshida, K; Yoshida, M | 1 |
| Abe, R; Aoyama, H; Asaga, T; Awane, H; Danno, M; Ikeda, T; Kimura, M; Koyama, H; Mitsuyama, S; Nishi, T; Ogita, M; Sano, M; Takashima, S; Takatsuka, Y; Toi, M; Tominaga, T; Wada, T; Yoshida, M | 1 |
| Aogi, K; Doihara, H; Nishimura, R; Ohsumi, S; Saeki, T; Taira, N; Takashima, S | 1 |
2 review(s) available for carmofur and tamoxifen
| Article | Year |
|---|---|
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; COVID-19; Disease Outbreaks; Drug Repositioning; Humans; Virus Internalization | 2021 |
[Recent development of oral anti-cancer drugs for breast cancer].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase II as Topic; Cyclophosphamide; Drug Administration Schedule; Fadrozole; Female; Floxuridine; Fluorouracil; Gonadotropin-Releasing Hormone; Humans; Medroxyprogesterone Acetate; Survival Rate; Tamoxifen; Toremifene | 1999 |
2 trial(s) available for carmofur and tamoxifen
| Article | Year |
|---|---|
Postoperative chemoendocrine therapy for women with node-positive stage II breast cancer with combined cyclophosphamide, tamoxifen, and 1-hexylcarbamoyl-5-fluorouracil.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoplasm Metastasis; Prospective Studies; Survival Rate; Tamoxifen | 2001 |
1-hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: a randomized controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Survival Rate; Tamoxifen | 2004 |
3 other study(ies) available for carmofur and tamoxifen
| Article | Year |
|---|---|
[Evaluation of neoadjuvant combination chemotherapy with pirarubicin, carmofur and tamoxifen citrate on outpatients with advanced and recurrence breast cancer].
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Doxorubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Outpatients; Tamoxifen; Treatment Outcome | 1994 |
[Successful endocrine chemotherapy in patients with multiple bone metastases of breast cancer--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Female; Floxuridine; Fluorouracil; Humans; Medroxyprogesterone; Middle Aged; Tamoxifen | 1999 |
S-1 (TS-1) maintained complete response for approximately 10 years in a case of metastatic breast cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Lung Neoplasms; Mastectomy, Modified Radical; Middle Aged; Neoplasm Staging; Remission Induction; Risk Assessment; Tamoxifen; Tegafur; Time Factors; Treatment Outcome | 2006 |